secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tourmaline Bio, Inc. (—)
CIK:        0001827506
Form:       8-K
Filed at:   2023-02-16T23:59:59+00:00
Accession:  0001193125-23-040697
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Talaris discontinues kidney transplant trials, cuts 1/3 of staff, explores strategic alternatives
--------------------------------------------------------------------------------

- Discontinues FREEDOM-1 and FREEDOM-2 kidney transplant trials due to slow enrollment; continues FREEDOM-3 scleroderma trial.
- Workforce reduced by ~1/3; remaining employees focus on cell therapy CMC and FREEDOM-3 trial.
- Expects ~$2.9M in restructuring costs in Q1-Q2 2023; cash position ~$181.3M as of Dec 31, 2022.
- Initiates comprehensive strategic review including possible business combinations or divestiture of cell therapy CMC.
- No timetable set for strategic review; suspends further program guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1827506/000119312523040697/0001193125-23-040697-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1827506/000119312523040697/d357370d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-040697

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer